In general, stocks under $1 are perceived as speculative investments because of their volatile nature.
Most penny stock investors purchase them to capitalize on a change in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In any case, to make an informed investment decision, a complete understanding of appropriate investments is necessary.
Socks Under $1 are extremely volatile, and they can easily drain clients’ funds. For this reason, educating yourself on penny stock fluctuations is crucial to avoiding losing investments. According to numerous studies, penny stocks can be just as beneficial as Fortune 500 companies when fundamentals, metrics, and developments are right.
Zosano Pharma Corporation (ZSAN)’s stock price was $0.63 at the previous market close, with its latest volume reaching 1.16 million. Compare that to its average daily volume of 1.92M. Given the fact that this stock has 108.94M shares outstanding, its current market value is sitting at $0.67.
For regular shareholders interested in finding out how worthwhile it would be to invest in the company, then note that Zosano Pharma Corporation has an ROE of -65.80%. An analysis will help understand that the lower the ROE figure; the worse a company is when it comes to generating profits. The term Return on Assets (ROA) is a ratio that points to a businesses’ profitability relative to overall assets. The company under our focus has a current ROA of -44.50%. If a business manages its assets well, then the ROA will be higher. However, the opposite will be true (lower returns) if that business is shown to be poor managers of their assets. A look at another ratio shows that Zosano Pharma Corporation has a Return on Investment (ROI) of -56.20%. When profits exceed costs, then the ROI percentage will be positive, and analysts will rate such business as having a net gain. However, if the percentage index is negative, then the company’s costs basically outweigh profits.
Timber Pharmaceuticals Inc. (AMEX: TMBR) does about 997.57K shares in volume on a normal day but saw 1.6 million shares change hands in Tuesday trading. The company now has a market cap of $34.21 million. Its current market price is $0.92, marking an increase of 2.42% compared to the previous close of $0.90. The 52 week high reached by this stock is $3.65 whilst the lowest price level in 52 weeks is $0.67. The script in recent trading has seen the stock touched a high of $0.97 and a low of $0.91.
TardiMed Sciences LLC, 10% Owner, of Timber Pharmaceuticals Inc. (TMBR), sold 50,000 shares of Timber Pharmaceuticals Inc. stock in an exchange that took place on Aug 20. The shares were sold at an average price of 0.91 each, amounting to a total Sale worth $45,395. As of the close of the sale, 10% Owner now directly holds 4,434,067 shares of the organization’s stock, which is now worth about $4079341.64. The deal was disclosed in a Securities & Exchange Commission legal filing, which can be publicly viewed on the SEC website.
The stock of Synthetic Biologics Inc. (SYN) increased by 4.74% to finish the standard trading session at $0.47. During that period, a total of 1.48 million shares were traded, and this stock’s average trading volume is currently 2.32M shares per day. Important things to pay attention to when considering a stock’s current and future price are the 52-week high and low price points. Shares of Synthetic Biologics Inc. (SYN) are currently -72.06% below their 52-week high mark and 81.99% higher than the 52-week low mark.
Wall Street analysts tracking the Synthetic Biologics Inc. (AMEX: SYN) stock on daily basis. Out of 1 analyst, 1 deeming the stock a Buy, and 0 gave it a rating of OVERWEIGHT. Another 0 recommended that syn is a HOLD, while 0 rated it UNDERWEIGHT and the 0 recommended SELL. If we look at the broader picture, the above ratings give the stock an average analyst rating of 2.00.
